BioAtla, Inc. (NASDAQ:BCAB) Short Interest Up 9.0% in March

BioAtla, Inc. (NASDAQ:BCAB) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 5,590,000 shares, a growth of 9.0% from the March 15th total of 5,130,000 shares. Based on an average daily trading volume, of 511,500 shares, the days-to-cover ratio is presently 10.9 days.

Analysts Set New Price Targets

A number of equities analysts have issued reports on BCAB shares. HC Wainwright cut their price objective on shares of BioAtla from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, March 27th. JMP Securities restated a “market outperform” rating and set a $12.00 price target on shares of BioAtla in a report on Thursday, March 28th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. UBS Group AG bought a new stake in BioAtla in the 3rd quarter valued at about $43,000. Point72 Hong Kong Ltd increased its stake in shares of BioAtla by 843.9% in the first quarter. Point72 Hong Kong Ltd now owns 8,561 shares of the company’s stock worth $43,000 after purchasing an additional 7,654 shares in the last quarter. Barclays PLC bought a new stake in shares of BioAtla in the second quarter valued at approximately $27,000. Quantbot Technologies LP lifted its stake in shares of BioAtla by 144.4% during the 1st quarter. Quantbot Technologies LP now owns 10,509 shares of the company’s stock valued at $52,000 after buying an additional 6,209 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in BioAtla in the 4th quarter worth approximately $88,000. 77.23% of the stock is owned by institutional investors.

BioAtla Price Performance

Shares of NASDAQ:BCAB opened at $2.63 on Wednesday. BioAtla has a 1 year low of $1.24 and a 1 year high of $4.07. The company has a market capitalization of $126.26 million, a PE ratio of -1.01 and a beta of 1.07. The business has a fifty day moving average price of $2.84 and a two-hundred day moving average price of $2.23.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.